ArticleParasites & vectors2026
Overcoming doramectin failure: field efficacy of pour-on 5% fluralaner and an experimental 1% oral formulation for the prevention of Cochliomyia hominivorax-associated umbilical myiasis in newborn calves.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMyiasis caused by Cochliomyia hominivorax larvae is a reemerging challenge in the Americas due to the recent reappearance of this species in areas where it had been eradicated and reports of doramectin inefficacy, despite its recognition as the most effective avermectin for prevention in cattle. As an alternative, 5% fluralaner administered via pour-on has shown 100% efficacy in the treatment and prevention of myiasis. Therefore, this study aimed to evaluate the efficacy of three antiparasitic treatments, namely 1% doramectin administered subcutaneously, 5% fluralaner pour-on, and 1% fluralaner administered orally, in preventing umbilical myiasis caused by C. hominivorax in newborn calves.
methodsThe study was conducted on a commercial beef cow-calf farm in Brazil. On day 0, during umbilical care, 200 newborn calves were randomly allocated to 4 groups: negative untreated control; 1% doramectin subcutaneously (200 µg/kg); 5% fluralaner pour-on (2.5 mg/kg); and 1% fluralaner orally (0.5 mg/kg, experimental formulation). All umbilical stumps were disinfected with 10% iodine tincture (10-30 s) without larvicidal compounds. Umbilical sites were evaluated on days 3, 7, and 14 for the presence of C. hominivorax larvae and lesion scores (0-3).
resultsThe results showed marked differences among treatments in the prevention of umbilical myiasis. In the control group, myiasis occurrence was 26% (95% CI 15-39%), confirming the high field risk of the disease. Treatment with 1% doramectin did not reduce (P = 0.8153) myiasis occurrence (22%; 95% CI 12.7-35.2%), showing a relative risk reduction of only 15.4%. Pour-on 5% fluralaner reduced myiasis occurrence to 4% (95% CI 1.1-13.4%), corresponding to a preventive efficacy of 84.6%. Despite proven 100% fluralaner efficacy, maternal licking may have contributed to the removal of the pour-on product in newborn calves, potentially reducing skin residues and being associated with the occurrence of umbilical myiasis. Orally administered 1% fluralaner showed 100% preventive efficacy. Umbilical lesion scores corroborated these findings, with a predominance of score 0 in fluralaner-treated groups.
conclusionsDoramectin was ineffective in preventing umbilical myiasis in newborn calves, whereas orally administered fluralaner showed 100% preventive efficacy. Pour-on fluralaner did not achieve complete preventive efficacy, possibly due to maternal licking at the product application site in calves.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.